Loading
A phase 1/2 trial of Carboplatin, Nedaplatin, Niraparib, Bevacizumab and Toripalimab in advanced solid tumours, run by Wigen Biomedicine Technology (Shanghai) Co., Ltd., now recruiting.
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06953323 by Wigen Biomedicine Technology (Shanghai) Co., Ltd., with 86 participants planned, started 2025-07-10 and due to reach its primary completion in 2029-06-30. Interventions recorded: WJB001 Capsules+Paclitaxel/Paclitaxel-albumin, WJB001 Capsules+carboplatin/Nedaplatin, WJB001 Capsules+Paclitaxel+carboplatin, WJB001 Capsules+Niraparib, WJB001 Capsules+Bevacizumab and WJB001 Capsules+JS207/JS001.
Shares WJB001, Wigen Biomedicine Technology (Shanghai), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Niraparib, Toripalimab, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bevacizumab, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bevacizumab, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Niraparib, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.